Business Services News

Business Services News

Breaking News on Business Services

Home > Business Services Search Engine                                 

Business Services News -- Video Feeds
  • Advertising
  • Careers
  • Corporate news
  • Economy
  • Markets
  • Small Business
  • Personal Finance
  • Regulatory and Compliance
  • Business News

    Global Monoclonal Antibodies Market Will Grow At A CAGR Of 10.6% Between 2010 And 2017 And To Reach $31.7 Billion By 2017
    (I-BusinessNews.Com, March 12, 2016 ) The leading business intelligence provider, has released its latest research Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products.

    The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market.

    GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and inhouse analysis by the GBI Research team of experts.

    GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.

    To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=25962

    Scope

    Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
    Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
    Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
    Key drivers and restraints that have had significant impact on the market.
    Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly

    Reasons to buy

    Build effective strategies to launch pipeline products, by identifying potential geographies.
    Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
    Develop key strategic initiatives by studying the key strategies of the top competitors.
    Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
    Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

    Browse Detail Report With TOC @ http://www.researchmoz.us/monoclonal-antibodies-market-to-2017-multiple-indication-approvals-and-the-potential-for-mabs-in-oncology-and-autoimmune-diseases-are-re-shaping-the-market-report.html

    Table of Contents

    1 Table of Contents
    1 Table of Contents 3
    1.1 List of Tables 8
    1.2 List of Figures 12

    2 Monoclonal Antibodies Market to 2017 - Introduction 15
    2.1 GBI Research Report Guidance 16

    3 Monoclonal Antibodies Market to 2017 - Market Characterization 17
    3.1 Introduction 17
    3.1.1 Stability in the Body 17
    3.1.2 Systemic Cancer Treatment 17
    3.1.3 Targeted Therapy 17
    3.2 Monoclonal Antibody Technology 18
    3.2.1 Hybridoma Technology 18
    3.2.2 FuCell Technology 18
    3.3 Revenue Forecasts Global 19
    3.3.1 Prescription Population 19
    3.3.2 Annual Cost of Therapy 20
    3.3.3 Revenue 22
    3.4 Revenue Forecasts Countrywise 23
    3.4.1 US 23
    3.4.2 Europe 24
    3.4.3 Rest of the World (ROW) 25
    3.5 Treatment Usage Patterns 26
    3.5.1 The US 26
    3.5.2 Europe 28
    3.5.3 ROW 29
    3.6 Annual Cost of Therapy 30
    3.6.1 The US 30
    3.6.2 Europe 31
    3.6.3 ROW 32
    3.7 Global MAbs Trends 33
    3.7.1 Market Trends 33
    3.7.2 Technology Trends 33
    3.8 Product Trends 33
    3.8.1 Research and Development Focus Shifted Towards Humanized and Fully Human MAbs 33
    3.9 Global MAbs Market Drivers 34
    3.9.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth 34
    3.9.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy 34
    3.9.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs 34
    3.9.4 Expanded Indications Opens up New Potential Patient Groups 34
    3.9.5 Lack of Generics Augmented the Sales Growth of MAbs 35
    3.10 Global MAbs Market Restraints 35
    3.10.1 High Cost of MAbs Hampering the Growth of Treatment Population 35
    3.10.2 Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy 35
    3.10.3 Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies 35
    3.11 Unmet Needs 36
    3.11.1 Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients 36
    3.11.2 MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation 36

    4 Monoclonal Antibodies Market to 2017 - Breast Cancer (Adjuvant and Metastatic) 37
    4.1 Overview 37
    4.2 Introduction 37
    4.3 Prescription Population 40
    4.3.1 Global 40
    4.3.2 The US 42
    4.3.3 Europe 43
    4.3.4 ROW 44
    4.4 Annual Cost of Therapy 45
    4.4.1 Global 45
    4.4.2 The US 46
    4.4.3 Europe 47
    4.4.4 ROW 48
    4.5 Market Size 49
    4.5.1 The US 50
    4.5.2 Europe 52
    4.5.3 ROW 53
    4.6 Marketed Products 54
    4.6.1 Herceptin (trastuzumab) 54
    4.7 Pipeline Analysis 55
    4.7.1 Phase lll 56
    4.7.2 Phase ll 58
    4.7.3 Phase l 61
    4.7.4 Preclinical/Discovery 62
    4.8 Promising Molecules 63
    4.8.1 Pertuzumab (2C4, trade name Omnitarg) 63
    4.8.2 Ramucirumab (IMC-1121B) 63

    5 MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy 64
    5.1 Introduction 64
    5.2 Epidemiology 65
    5.3 Diagnosis 65
    5.4 Treatment 65
    5.5 Prescription Population 66
    5.5.1 Global 66
    5.5.2 The US 67
    5.5.3 Europe 68
    5.5.4 ROW 69
    5.6 Annual Cost of Therapy 70
    5.6.1 Global 70
    5.6.2 The US 71
    5.6.3 Europe 72
    5.6.4 ROW 73
    5.7 Market Size 74
    5.7.1 Global 74
    5.7.2 The US 75
    5.7.3 Europe 76
    5.7.4 ROW 77
    5.8 Marketed Products 78
    5.8.1 Xgeva (denosumab) 78
    5.9 Pipeline Analysis 79
    5.9.1 NDA Filed 79
    5.9.2 Phase ll 79
    5.9.3 Phase l 79
    5.9.4 Preclinical/Discovery 79

    6 MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS) 80
    6.1 Introduction 80
    6.2 Epidemiology 80
    6.3 Diagnosis 80
    6.4 Treatment 81
    6.5 Prescription Population 81
    6.5.1 Global 81
    6.5.2 The US 83
    6.5.3 Europe 84
    6.5.4 ROW 85
    6.6 Annual Cost of Therapy 86
    6.6.1 Global 86
    6.6.2 The US 87
    6.6.3 Europe 88
    6.6.4 ROW 89
    6.7 Market Size 90
    6.7.1 Global 90
    6.7.2 The US 91
    6.7.3 Europe 92
    6.7.4 ROW 93
    6.8 Marketed Products 94
    6.8.1 Description 94
    6.8.2 Mechanism of Action 94
    6.8.3 Indications and Usage 94
    6.8.4 Dosage 94
    6.9 Pipeline Analysis 95
    6.9.1 Phase lll 95
    6.9.2 Phase ll 95
    6.9.3 Phase l 96
    6.9.4 Preclinical/Discovery 96
    6.10 Promising Molecules 96
    6.10.1 Campath (Alemtuzumab) 96
    6.10.2 Ocrelizumab 97

    7 MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC) 98
    7.1 Introduction 98
    7.2 Epidemiology 98
    7.3 Diagnosis 98
    7.4 Prescription Population 100
    7.4.1 Global 100
    7.4.2 The US 101
    7.4.3 Europe 102
    7.4.4 ROW 103
    7.5 Annual Cost of Therapy 104
    7.5.1 Global 104
    7.5.2 The US 105
    7.5.3 Europe 106
    7.5.4 ROW 107
    7.6 Market Size 108
    7.6.1 Global 108
    7.6.2 The US 109
    7.6.3 Europe 110
    7.6.4 ROW 111
    7.7 Marketed Products 112
    7.7.1 Avastin 112
    7.8 Pipeline Analysis 112
    7.8.1 Phase III 113
    7.8.2 Phase II 114
    7.8.3 Phase I 119
    7.9 Promising Molecule 120
    7.9.1 Necitimumab 120
    7.9.2 Ramucirumab 121

    8 Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis 122
    8.1 Introduction 122
    8.2 Epidemiology 122
    8.3 Diagnosis 122
    8.4 Treatment 123
    8.5 Prescription Population 124
    8.5.1 Global 124
    8.5.2 The US 125
    8.5.3 Europe 126
    8.5.4 ROW 127
    8.6 Annual Cost of Therapy 128
    8.6.1 Global 128
    8.6.2 The US 129
    8.6.3 Europe 130
    8.6.4 ROW 131
    8.7 Market Size 132
    8.7.1 Global 132
    8.7.2 The US 133
    8.7.3 Europe 134
    8.7.4 ROW 135
    8.8 Marketed Products 136
    8.8.1 Rituxan 136
    8.8.2 Remicade 136
    8.8.3 Humira 136
    8.8.4 Cimzia 136
    8.8.5 Simponi 137
    8.8.6 Actemra 137
    8.9 Pipeline Analysis 138
    8.9.1 Phase III 138
    8.9.2 Phase II 139
    8.9.3 Phase I 140
    8.9.4 Preclinical/ Discovery Phase 140
    8.10 Promising Molecule 141
    8.10.1 Ofatumumab (Arzerra) 141
    8.10.2 SAR153191(REGN88) 141

    9 Monoclonal Antibodies Market to 2017 - Competitive Landscape 143
    9.1 Market Share Analysis 143
    9.1.1 Major Companies 143
    9.2 Amgen Inc 143
    9.3 Abbott Laboratories 145
    9.4 Johnson & Johnson 146
    9.5 Novartis AG 147
    9.6 Biogen Idec 148
    9.7 Merck & Co Inc 149
    9.7.1 Company Profile 149
    9.7.2 Marketed Products 149
    9.7.3 SWOT Analysis 149
    9.8 Eli Lilly and Company 150
    9.8.1 Company Profile 150
    9.8.2 Marketed Products 150
    9.8.3 SWOT Analysis 150
    9.9 Roche 151
    9.9.1 Company Profile 151
    9.9.2 Marketed Products 151
    9.9.3 SWOT Analysis 151

    10 Monoclonal Antibodies Market to 2017 - Strategic Consolidations 152
    10.1 Deal Type 152
    10.2 Mergers & Acquisitions 152
    10.2.1 By Geography 152
    10.2.2 M&A by Year 153
    10.2.3 M&A by Value 154
    10.2.4 Top M&A Deals 155
    10.3 Licensing Agreement 157
    10.3.1 By Geography 157
    10.3.2 By Year 157
    10.3.3 By Value 158
    10.3.4 Licensing Agreement Deals by Value 158
    10.3.5 Top Five Licensing Deals 161
    10.4 Partnerships 163
    10.4.1 By Geography 163
    10.4.2 By Year 163
    10.4.3 By Value 164

    11 Monoclonal Antibodies Market to 2017 - Appendix 167
    11.1 Market Definitions 167
    11.2 Abbreviations 167
    11.3 Research Methodology 167
    11.3.1 Coverage 167
    11.3.2 Secondary Research 168
    11.3.3 Primary Research 168
    11.3.4 Therapeutic Landscape 169
    11.3.5 Geographical Landscape 171
    11.3.6 Pipeline Analysis 171
    11.3.7 Competitive Landscape 171
    11.3.8 Expert Panel Validation 171
    11.4 Contact Us 171
    11.5 Disclaimer 172
    11.6 Sources 172

    Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=25962

    About ResearchMoz

    ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

    For More Information Kindly Contact:

    ResearchMoz
    Mr. Nachiket Ghumare,
    Tel: +1-518-621-2074
    USA-Canada Toll Free: 866-997-4948
    Email: sales@researchmoz.us

    Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease

    Researchmoz Global Pvt.Ltd

    Researchmoz

    +1-518-621-2074

    sales@researchmoz.us

    Source: EmailWire.Com

    Source: EmailWire.com

    Business News Feeds
  • Business News - Top Stories
  • Company Earnings
  • Economy
  • Personal Finance
  • Real Estate
  • Stock Markets
  • Business Services Sponsors

    Business Services Ads

    Business Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    CIO Insight
    Managed Healthcare Executive
    Mortgage Technology

    No credit cards, coupons, or promo codes required. Try it today!

    Press release service

    :: Home: :: Submit Press Release :: Subscribe to News :: Contact Us :: Help

    For unlimited press release distribution for $59 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com.

    Copyright 2008 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
    I-BusinessNews.Com is a business news service of GroupWeb Media LLC